MCID: LKM062
MIFTS: 64

Leukemia, Acute Lymphoblastic

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases, Genetic diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 53 71 13 13 13 13 37
Acute Lymphoblastic Leukemia 37 72 49 28
All 53 49 71
Leukemia, Acute Lymphoblastic, Susceptibility to 28 13
Acute Lymphocytic Leukemia 49 69
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 69
Leukemia, Acute Lymphocytic, Susceptibility to, 1 53
Precursor Cell Lymphoblastic Leukemia Lymphoma 69
Leukemia Acute Lymphoblastic B-Hyperdiploid 71
Childhood Acute Lymphoblastic Leukemia 71
Leukemia, T-Cell Acute Lymphoblastic 13
Leukemia, Acute T-Cell Lymphoblastic 13
Leukemia B-Cell Acute Lymphoblastic 71
Leukemia T-Cell Acute Lymphoblastic 71
Leukemia, Acute Lymphoblastic, 3 71
Leukemia, Lymphocytic, Acute, L1 69
Leukemia Acute Lymphoblastic 1 71
Leukemia, Acute Lymphocytic 1 53
Leukemia Acute Lymphocytic 1 71
Lymphoblastic Leukemia Acute 51
Leukemia, Acute Lymphocytic 13
Leukemia Acute Lymphocytic 71
All3 71
All1 71

Characteristics:

HPO:

31
leukemia, acute lymphoblastic:
Inheritance polygenic inheritance


Classifications:



Summaries for Leukemia, Acute Lymphoblastic

NIH Rare Diseases : 49 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments. Last updated: 10/31/2017

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to acute lymphoblastic leukemia, childhood and precursor t-cell acute lymphoblastic leukemia, and has symptoms including acute lymphoblastic leukemia, edema and chest pain. An important gene associated with Leukemia, Acute Lymphoblastic is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Pathways in cancer and Chronic myeloid leukemia. The drugs Arranon and Blincyto have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are cellular and growth/size/body region

OMIM : 53 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065)

UniProtKB/Swiss-Prot : 71 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes. Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 72 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic 2
Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 acute lymphoblastic leukemia, childhood 34.5 ABCB1 ETV6 FLT3 RUNX1
2 precursor t-cell acute lymphoblastic leukemia 33.6 ABL1 BAX BCL10 BCR ETV6 FLT3
3 leukemia, acute lymphoblastic 3 33.6 ABL1 BCR CD19 ETV6 FLT3 KMT2A
4 b-cell adult acute lymphocytic leukemia 33.3 ABL1 PAX5
5 acute lymphocytic leukemia 33.2 ABCB1 ACTB BCR ETV6 NBN PAX5
6 lymphoblastic leukemia, acute, with lymphomatous features 33.1 ACTB NBN
7 lymphoblastic leukemia 30.9 ABL1 BAX BCR ETV6 FLT3 NBN
8 leukemia 30.8 ABL1 BAX BCR ETV6 FLT3 KMT2A
9 childhood leukemia 30.2 ABL1 ETV6 KMT2A RUNX1
10 acute leukemia 30.1 ABCB1 ETV6 FLT3 KMT2A PAX5 RUNX1
11 myeloid leukemia 30.0 ABL1 BCR ETV6 FLT3 PICALM RUNX1
12 leukemia, acute myeloid 29.6 ABCB1 ABL1 BCR CD19 ETV6 FLT3
13 b-cell childhood acute lymphoblastic leukemia 12.5
14 leukemia, acute lymphoblastic 2 12.3
15 acute lymphoblastic leukemia congenital sporadic aniridia 12.1
16 t-cell childhood acute lymphocytic leukemia 11.8
17 acute t cell leukemia 11.5
18 ring chromosome 21 10.6 ETV6 KMT2A
19 philadelphia-negative chronic myeloid leukemia 10.6 ABL1 BCR
20 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.6 FLT3 RUNX1
21 platelet disorder, familial, with associated myeloid malignancy 10.6 ETV6 RUNX1
22 myeloid sarcoma 10.6 FLT3 KMT2A PAX5
23 8p11 myeloproliferative syndrome 10.6 BCR FLT3 RUNX1
24 chronic myelomonocytic leukemia 10.5 ETV6 FLT3 RUNX1
25 lymphoid leukemia 10.5 BCR ETV6 KMT2A RUNX1
26 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5 ETV6 FLT3 KMT2A RUNX1
27 central nervous system leukemia 10.5 CD19 RUNX1
28 myeloproliferative neoplasm 10.5 ABL1 BCR ETV6
29 mn1 10.5 ETV6 FLT3
30 cytogenetically normal acute myeloid leukemia 10.5 FLT3 KMT2A
31 bone marrow cancer 10.4 ABL1 BCR ETV6 FLT3 RUNX1
32 acute promyelocytic leukemia 10.4 ABCB1 BAX FLT3 RUNX1
33 burkitt lymphoma 10.4 BAX BCR PAX5
34 leukemia, chronic myeloid 10.4 ABCB1 ABL1 BCR ETV6 FLT3 RUNX1
35 leukemia, chronic lymphocytic 10.3 ABCB1 BAX BCL10 BCR CD19 PAX5
36 myelodysplastic syndrome 10.3 ABL1 ETV6 FLT3 KMT2A RUNX1
37 bladder lymphoma 10.3 CD19 PAX5
38 lymphoma, non-hodgkin, familial 10.3 ABCB1 BAX BCL10 BCR CD19 NBN
39 hepatosplenic t-cell lymphoma 10.2 ABCB1 SETD2
40 hematologic cancer 10.1 ABCB1 ABL1 BCR ETV6 FLT3 KMT2A
41 lymphoma 9.7

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Clinical features from OMIM:

613065

Human phenotypes related to Leukemia, Acute Lymphoblastic:

31
# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 31 HP:0006721

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 PICALM RUNX1 ABL1 BAX BCL10 BCR
2 growth/size/body region MP:0005378 10.35 PICALM RUNX1 SETD2 ABCB1 ABL1 ACTB
3 hematopoietic system MP:0005397 10.34 RUNX1 SETD2 ABCB1 ABL1 ACTB BAX
4 behavior/neurological MP:0005386 10.33 ACTB BAX BCR CD19 CDKN2C GNB1
5 homeostasis/metabolism MP:0005376 10.25 ABCB1 ABL1 ACTB BAX BCR CD19
6 immune system MP:0005387 10.24 FLT3 KMT2A NBN PAX5 PICALM RUNX1
7 embryo MP:0005380 10.21 ABL1 ACTB BCL10 ETV6 GNB1 KMT2A
8 cardiovascular system MP:0005385 10.19 ABCB1 ABL1 ACTB CD19 CDKN2C ETV6
9 endocrine/exocrine gland MP:0005379 10.19 ABCB1 ABL1 ACTB BAX BCL10 CDKN2C
10 mortality/aging MP:0010768 10.19 ABCB1 ABL1 ACTB BAX BCL10 BCR
11 hearing/vestibular/ear MP:0005377 9.93 ACTB BAX BCR KMT2A PAX5 ABCB1
12 liver/biliary system MP:0005370 9.92 ABCB1 ABL1 ACTB BCR CD19 KMT2A
13 neoplasm MP:0002006 9.85 ACTB BAX CD19 CDKN2C ETV6 FLT3
14 nervous system MP:0003631 9.8 ABCB1 ABL1 ACTB BAX BCL10 BCR
15 normal MP:0002873 9.23 ABL1 ACTB BCR CD19 ETV6 KMT2A

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

FDA approved drugs:

(show all 7)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 45 NELARABINE GlaxoSmithKline October 2005
2
Blincyto 17 45 BLINATUMOMAB Amgen December 2014
3
Clolar 17 45 CLOFARABINE Genzyme December, 2004
4
Erwinaze 17 45 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
5
Iclusig 17 45 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
6
Marqibo 17 45 VINCRISTINE SULFATE Talon Therapeutics August 2012
7
Sprycel 17 45 DASATINIB Bristol-Myers Squibb June 2006

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 615)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 302962-49-8 3062316
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
5
Asparaginase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
6
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 147-94-4 6253
7
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
8
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
10
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
11
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
14
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
15
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
16
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130167-69-0
17
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 1 4291-63-8 20279
18
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
19
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
20
Teniposide Approved Phase 4,Phase 3,Phase 2 29767-20-2 34698
21
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
22
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2 53643-48-4, 59917-39-4 40839
23
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
24
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
25
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
26 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
27
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
29
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
30
Methylphenidate Approved, Investigational Phase 4 20748-11-2, 113-45-1 4158
31
Oprelvekin Approved, Investigational Phase 4 145941-26-0
32
Menthol Approved Phase 4 2216-51-5 16666
33
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
34
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
35
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
36
Nicotine Approved Phase 4 54-11-5 89594 942
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
39
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
40
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
41
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
42
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 31703
43
Butyric Acid Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264
44
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
45 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1721)

# Name Status NCT ID Phase Drugs
1 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
2 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
3 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
4 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
5 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
6 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
7 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
8 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
9 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Unknown status NCT02290132 Phase 4 Rabbit Anti-human Thymocyte Globulin (ATG)
10 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
11 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
12 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
13 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
14 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
15 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
16 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
17 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
18 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
19 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
20 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
21 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
22 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
23 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4 rhIL-11
24 The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
25 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
26 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
27 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
28 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
29 Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
30 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Recruiting NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
31 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Recruiting NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
32 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
33 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
34 PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
35 Vaccinating Children After Chemotherapy Recruiting NCT02447718 Phase 4
36 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
37 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Recruiting NCT02036489 Phase 4 Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
38 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
39 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Active, not recruiting NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
40 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Active, not recruiting NCT01200355 Phase 4 micafungin;posaconazole
41 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
42 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
43 ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
44 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL Terminated NCT00299234 Phase 4 Atomoxetine
45 Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia Unknown status NCT02072785 Phase 3 Vincristine Sulfate Liposome;Vincristine Sulfate
46 Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
47 High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
48 Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia Unknown status NCT00003437 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;thioguanine;vincristine sulfate
49 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
50 Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia: Unknown status NCT02070523 Phase 3 VDCLD regimen

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to 28
2 Acute Lymphoblastic Leukemia 28

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

38
T Cells, Bone, Bone Marrow, B Cells, Myeloid, Liver, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

# Title Authors Year
1
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. ( 10637482 )
2000
2
Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. ( 7694687 )
1993

Variations for Leukemia, Acute Lymphoblastic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

71
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh37 Chromosome 19, 49459056: 49459056
2 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh37 Chromosome 19, 49458972: 49458978
3 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh37 Chromosome 13, 28592641: 28592641
4 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
5 FLT3 NM_004119.2(FLT3): c.1777_1779delGAT (p.Asp593del) deletion Pathogenic rs587776834 GRCh38 Chromosome 13, 28034140: 28034142
6 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 GRCh38 Chromosome 8, 89943297: 89943297
7 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh37 Chromosome 12, 12038855: 12038859
8 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh37 Chromosome 12, 12037415: 12037415
9 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh37 Chromosome 1, 85736511: 85736511
10 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant risk factor rs61754966 GRCh37 Chromosome 8, 90990521: 90990521
11 ACTB NP_001092.1(ACTB): p.Val209Leu protein only Pathogenic
12 GNB1 NM_002074.4(GNB1): c.239T> A (p.Ile80Asn) single nucleotide variant Pathogenic rs752746786 GRCh37 Chromosome 1, 1737942: 1737942
13 GNB1 NM_002074.4(GNB1): c.227A> G (p.Asp76Gly) single nucleotide variant Pathogenic rs869312821 GRCh38 Chromosome 1, 1806515: 1806515
14 NBN NM_002485.4(NBN): c.156_157delTT (p.Ser53Cysfs) deletion Pathogenic/Likely pathogenic rs767454740 GRCh37 Chromosome 8, 90994964: 90994965

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AFARP1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5F1 Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss C1orf103 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss C1orf152 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss C1orf161 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss C1orf183 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7 Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia

Expression for Leukemia, Acute Lymphoblastic

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.

Pathways for Leukemia, Acute Lymphoblastic

GO Terms for Leukemia, Acute Lymphoblastic

Cellular components related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.47 ABL1 ACTB BAX BCL10 BCR CDKN2C
2 protein complex GO:0043234 9.43 ABL1 ACTB BCL10 BCR CD19 FLT3

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of hematopoietic stem cell differentiation GO:1902036 9.67 ABL1 KMT2A RUNX1
2 post-embryonic development GO:0009791 9.63 ABL1 BAX KMT2A
3 neural tube closure GO:0001843 9.61 ABL1 BCL10 SETD2
4 hemopoiesis GO:0030097 9.58 FLT3 PICALM RUNX1
5 definitive hemopoiesis GO:0060216 9.51 BCR KMT2A
6 hematopoietic stem cell proliferation GO:0071425 9.48 ETV6 RUNX1
7 peptidyl-lysine monomethylation GO:0018026 9.37 KMT2A SETD2
8 neuromuscular process controlling balance GO:0050885 9.33 ABL1 BCR NBN
9 regulation of B cell receptor signaling pathway GO:0050855 9.32 PAX5 RUNX1
10 B cell apoptotic process GO:0001783 9.26 BAX BCL10
11 leukocyte homeostasis GO:0001776 8.96 BAX FLT3
12 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 8.8 ABL1 BAX CD19

Molecular functions related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 ABCB1 ABL1 ACTB BAX BCL10 BCR

Sources for Leukemia, Acute Lymphoblastic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....